Clinical trial

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

NCT00577122

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-07-01

PhasePHASE2

Study timeline

Study start (unknown)2007-07-01Date precision: month

Registry last updated2023-10-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Estrogen Receptor-negative Breast Cancerunresolved

Progesterone Receptor-negative Breast Cancerunresolved

Recurrent Breast Cancerunresolved

Stage IV Breast Cancerunresolved

Interventions

Medroxyprogesterone progesterone acetate (MPA)DRUG

Medroxyprogesterone with Cyclophosphamide + MethotrexateDRUG

Sponsors & collaborators

Indiana Universitylead sponsor

Translational Breast Cancer Research Consortiumcollaborator

Mapped research locations

HoustonTexas, United States1 BostonMassachusetts, United States1 San FranciscoCalifornia, United States1 BirminghamAlabama, United States1 DurhamNorth Carolina, United States1 IndianapolisIndiana, United States1 Chapel HillNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00577122 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.